4/2024 | TAE
TAE Life Sciences, proudly announces the successful completion of acceptance testing and regulatory registration inspection of its accelerator- based neutron beam system (NBS), marking a significant milestone in BNCT global market adoption.
3/2024 | TAE Life Sciences
TAE Life Sciences, a leading innovator in cancer treatment
technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted the company’s U.S. Patent No. US 11,884,688 B2, for its groundbreaking borylated amino acid compositions comprising tyrosine derivatives BTS and BTS(OMe)
11/2023 | TAE Life Sciences
Earning the BioTech Breakthrough Award for Oncology Innovation of the Year validates the progress TAE Life Sciences has made in readying its Alphabeam BNCT system for clinical trials worldwide
9/2023 | TAE Life Sciences
TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, is thrilled to announce it is bringing BNCT to this year's annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.
9/2023 | TAE Life Sciences
TAE Life Sciences (TLS), a pioneer in accelerator-based Boron Neutron Capture Therapy, announces its participation in the upcoming LSI Europe 2023 conference. The event, set to take place in Barcelona from September 18-22, will serve as a platform for TAE Life Sciences' CEO, Rob Hill, to deliver a keynote presentation on the future of radiation oncology, and the company's revolutionary BNCT system and proprietary BNCT drugs.
8/2023 | PR Newswire
TAE Life Sciences has today announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino acid analog drug for boron neutron capture therapy (BNCT). As part of this exclusive agreement, Biddle Sawyer has enlisted contract research and manufacturing organization Kinentia Biosciences to refine and streamline the drug's manufacturing process, and ultimately produce the drug in their state-of-the-art GMP facility. Kinentia Biosciences will be the exclusive manufacturer of TC220 for the US market.
TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
Bruce Bauer, Ph.D., CEO of TAE Life Sciences. The company is developing boron neutron capture therapy (BNCT) as a new radiation therapy for cancer. A patient is first infused with a non-toxic boron-10 compound, which selectively accumulates in tumor tissue. A neutron beam is then focused on the tumor and the neutrons are captured by the boron and causes emission of alpha radiation particles within the tumor.
BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10.
HEALTHCARE: SPIN-OFF FROM FUSION COMPANY AIMING BIG
Nanotechnology is the application of extremely small things—a nanometer is one billionth of a meter—used in science, engineering and technology. It involves the ability to view and control individual atoms and molecules and has been used in designing new therapeutics and diagnostics in medicine. As such, interest is mounting to harness nanotechnology’s potential to enhance radiation therapy and advance cancer care.
BNCT may provide a new option for patients with GBM and head and neck cancers due to its ability to leave healthy tissue unharmed.
TAE Life Sciences, a medical technology company developing an accelerator-based platform for clinical investigation of a promising, previously inaccessible cancer treatment, made its public debut today.
TAE Life Sciences said yesterday it raised $40 million in venture capital to support the development of its neutron beam technology designed as a potential treatment for head and neck, glioblastoma multiforme and other cancers.
Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.
TAE Life Sciences aims to commercialize a cancer radiation treatment called Boron Neutron Capture Therapy. In BNCT, boron-10 is administered to tumors, irradiated with a beam of neutrons, and broken down into charged particles that kill cancer cells.
There’s a radiological medical technique called Boron Neutron Capture Therapy (BNCT), which is like a very targeted chemotherapy.
The neutron beam is aimed at the cancer patient’s tumors for about 30 minutes, and is combined with a boron-based substance that is injected into the patient intravenously and accumulates in the cancer cells.
Boron Neutron Capture Therapy (BNCT) is a targeted radiation therapy that combines low-energy neutrons with target boron drugs that generate cancer killing alpha and lithium particles. BNCT is going through a renaissance driven by new accelerator-based, in-hospital neutron source technology and novel targeted boron drugs.
Join our complimentary webinar to learn more about the modality and clinical adoption our experts.
